肺気腫治療の世界市場と産業規模、シェア、動向、機会、予測、2018年～2028年：治療法別、流通チャネル別、エンドユーザー別、地域別、競合

世界の肺気腫治療市場は2022年に42億1,000万米ドルと評価され、2028年までのCAGRは5.68%で、予測期間中に力強い成長が予測されています。

世界の肺気腫治療市場は、慢性閉塞性肺疾患（COPD）である肺気腫の有病率の増加を主な要因として、ヘルスケア産業の中でダイナミックかつ急速に発展している分野です。肺気腫は肺組織の破壊を特徴とし、息切れや肺機能の低下につながります。この衰弱状態は、たばこの煙や環境汚染物質、その他の危険因子に長期間さらされることによって引き起こされることが多いです。その結果、効果的な肺気腫治療薬に対する需要は増加傾向にあり、同市場の成長に拍車をかけています。

世界の肺気腫治療市場の成長を支える主な要因の1つは、革新的な治療法や介入策を見出すことを目的とした継続的な研究開発努力です。肺気腫の従来の治療法には、主に薬物療法、酸素療法、肺リハビリテーションなどがあります。しかし、最近の医療技術の進歩により、気管支鏡下肺容量減少術（BLVR）や肺移植のような低侵襲手術が登場し、重度の肺気腫患者に新たな希望をもたらしています。

さらに市場は、肺気腫の進行に関与する特定の経路を標的とする気管支拡張薬、抗炎症薬、生物学的製剤を含む、新規の医薬品や治療法の流入を目の当たりにしています。これらの革新的な治療法は、患者の生活の質を改善し、疾患の進行を遅らせることを目的としています。しかし、高額な治療費、特定の地域における先進治療へのアクセスの制限、新しい治療法の有効性と安全性を確立するための厳密な臨床試験の必要性などの課題は、依然として市場拡大の障害となっています。

市場促進要因

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 肺気腫治療の世界市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 治療法別（禁煙、気管支拡張薬、ステロイド、ロイコトリエン調節薬、補助酸素、抗生物質、遺伝子治療、手術移植、その他の治療法）
  • 流通チャネル別（病院薬局、小売薬局、その他の流通チャネル）
  • エンドユーザー別（病院・クリニック、外来診療センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 治療薬別
  • 流通チャネル別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の肺気腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 流通チャネル別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の肺気腫治療市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 流通チャネル別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の肺気腫治療市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 流通チャネル別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の肺気腫治療市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 流通チャネル別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの肺気腫治療市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療薬別
  • 流通チャネル別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の肺気腫治療市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Icure Pharmaceuticals Inc.
• AstraZeneca Plc.
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• GlaxoSmithKline Plc.
• Hikma Pharmaceuticals Plc
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Pfizer Inc.
• Orion Corporation

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Emphysema Treatment Market has valued at USD 4.21 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.68% through 2028. The Global Emphysema Treatment Market is a dynamic and rapidly evolving sector within the healthcare industry, primarily driven by the increasing prevalence of emphysema, a chronic obstructive pulmonary disease (COPD). Emphysema is characterized by the destruction of lung tissue, leading to shortness of breath and reduced lung function. This debilitating condition is often caused by long-term exposure to tobacco smoke, environmental pollutants, and other risk factors. As a result, the demand for effective emphysema treatments has been on the rise, fueling the growth of this market.

One of the key drivers behind the growth of the Global Emphysema Treatment Market is the continuous research and development efforts aimed at finding innovative therapies and interventions. Traditional treatments for emphysema primarily include medications, oxygen therapy, and pulmonary rehabilitation. However, recent advancements in medical technology have led to the emergence of minimally invasive procedures like bronchoscopic lung volume reduction (BLVR) and lung transplantation, offering new hope to patients with severe emphysema.

Furthermore, the market is witnessing an influx of novel pharmaceutical products and therapies, including bronchodilators, anti-inflammatory drugs, and biologics that target specific pathways involved in emphysema progression. These innovative treatments aim to improve patients' quality of life and slow down the disease's progression. However, challenges such as high treatment costs, limited access to advanced therapies in certain regions, and the need for rigorous clinical trials to establish the efficacy and safety of new treatments remain hurdles in the market's expansion.

Key Market Drivers

Advancements in Medical Technology

Advancements in medical technology are playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a debilitating chronic obstructive pulmonary disease (COPD), has historically posed significant challenges in treatment. However, recent breakthroughs in medical technology are revolutionizing the landscape of emphysema management.

Minimally invasive procedures like bronchoscopic lung volume reduction (BLVR) have emerged as a game-changer in emphysema treatment. BLVR involves the insertion of small devices or materials into the airways to block off or reduce airflow to damaged areas of the lungs. This procedure helps improve lung function and alleviate symptoms, offering a lifeline to patients with severe emphysema who were previously deemed untreatable. BLVR not only reduces the burden of invasive surgery but also enhances patient outcomes and quality of life.

Biologics and targeted therapies represent another breakthrough in emphysema treatment. These pharmaceutical innovations are designed to specifically target the underlying molecular pathways responsible for emphysema progression. By intervening at the molecular level, biologics can slow down the disease's advancement and improve patients' respiratory function. This approach is not only more effective but also less invasive compared to traditional treatment options like long-term corticosteroids or bronchodilators.

Furthermore, technological advancements have led to improved diagnostic tools and monitoring devices. High-resolution computed tomography (HRCT) scans, for instance, provide more accurate and detailed images of lung damage caused by emphysema. These diagnostic improvements enable healthcare professionals to assess the severity of the disease and tailor treatment plans more precisely.

Rising Prevalence of Emphysema

The rising prevalence of emphysema is a significant driving force behind the growth of the Global Emphysema Treatment Market. Emphysema, a chronic obstructive pulmonary disease (COPD), is characterized by the progressive destruction of lung tissue, leading to severe respiratory difficulties and reduced lung function. The primary risk factors for emphysema include long-term exposure to tobacco smoke, environmental pollutants, and occupational hazards, all of which have become increasingly prevalent in modern society.

As the global population ages and these risk factors persist, the prevalence of emphysema continues to climb. The World Health Organization (WHO) estimates that COPD, including emphysema, is already the third leading cause of death worldwide, and this burden is expected to increase further in the coming years. In many developed countries, an aging population contributes to a higher prevalence of emphysema, as the disease is more common among older individuals.

Furthermore, the link between emphysema and other health conditions, such as heart disease and diabetes, underscores the urgency of addressing this disease. It places a substantial burden on healthcare systems, with increased hospitalizations and healthcare costs. As a result, both healthcare providers and policymakers are recognizing the importance of early diagnosis and effective treatment to mitigate the impact of emphysema on individuals and healthcare resources.

The rising awareness of emphysema and COPD in general is also contributing to the market's growth. Public health initiatives, educational campaigns, and advocacy groups have been instrumental in increasing awareness about the risks associated with smoking, environmental pollution, and the importance of early detection and management of respiratory diseases. This heightened awareness encourages individuals to seek medical attention at an earlier stage of the disease, enabling timely intervention and treatment.

Increasing Awareness and Education

Increasing awareness and education are playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a severe form of chronic obstructive pulmonary disease (COPD), has long been underdiagnosed and undertreated. However, concerted efforts in education and awareness campaigns are changing this narrative.

Public health initiatives and advocacy groups have been actively raising awareness about the risks associated with emphysema and COPD. These efforts have focused on the dangers of smoking, environmental pollution, and the importance of early detection and treatment. As a result, more individuals are becoming informed about the risk factors and symptoms of emphysema, leading to early diagnosis and intervention.

Increased awareness has led to a significant shift in patient behavior. Individuals are now more likely to seek medical attention when they experience symptoms like shortness of breath and chronic cough, which are often early indicators of emphysema. This proactive approach allows for timely diagnosis and the initiation of appropriate treatments, ultimately improving patient outcomes.

Moreover, healthcare providers are increasingly educated about the latest advancements in emphysema treatment options. They are better equipped to recognize the disease and recommend appropriate therapies. This not only benefits patients but also supports the growth of the emphysema treatment market as healthcare professionals actively engage in providing innovative treatments to their patients.

Research funding has also seen an uptick due to increased awareness. With a greater understanding of the disease's impact and the urgent need for effective treatments, both public and private sectors are investing in research and development efforts. This has led to the development of new and innovative therapies, further expanding the treatment options available to individuals with emphysema.

Key Market Challenges

High Treatment Costs

High treatment costs are a significant barrier hindering the advancement of the Global Emphysema Treatment Market. Emphysema, a debilitating chronic obstructive pulmonary disease (COPD), affects millions of individuals worldwide, and managing this condition can be financially burdensome for both patients and healthcare systems.

The development of innovative emphysema treatments, such as bronchoscopic lung volume reduction (BLVR) procedures and targeted biologics, has offered new hope to patients by providing potentially more effective and less invasive options. However, these cutting-edge treatments often come with a hefty price tag.

For many emphysema patients, the high cost of treatment represents a substantial financial barrier. Coping with the financial burden of these therapies can be overwhelming, particularly for those without comprehensive health insurance coverage. High deductibles, copayments, and out-of-pocket expenses can strain patients' finances and limit their access to essential treatments.

Additionally, emphysema is a chronic condition that often requires ongoing care, including medications, regular check-ups, and pulmonary rehabilitation. These long-term expenses further compound the financial challenges faced by patients, potentially forcing them to make difficult choices between healthcare and other essential needs.

The burden of high treatment costs also extends to healthcare systems and governments. As the prevalence of emphysema continues to rise, the strain on healthcare budgets becomes more pronounced. The cost of providing advanced treatments and therapies can lead to allocation challenges, diverting resources from other critical healthcare needs.

Long-Term Disease Management

Long-term disease management poses a significant hindrance to the advancement of the Global Emphysema Treatment Market. Emphysema, a form of chronic obstructive pulmonary disease (COPD), is a progressive lung condition that requires ongoing care and management. While innovative treatments and interventions have emerged, effectively managing emphysema over the long term presents several challenges for both patients and healthcare systems.

Emphysema patients often require continuous access to medications, therapies, and medical supervision to maintain their quality of life. This entails a substantial financial burden on healthcare systems, as the cost of providing long-term care and medication can be significant. For patients, ensuring consistent access to treatment can be challenging, especially for those with limited financial resources or inadequate health insurance coverage.

Lifestyle modifications are a crucial aspect of emphysema management, including smoking cessation, regular exercise, and dietary changes. Encouraging patients to adopt and maintain these changes over the long term can be a formidable challenge. Patients may struggle with motivation, and the burden of self-management can lead to non-compliance with recommended lifestyle adjustments.

Furthermore, emphysema is a dynamic disease, meaning that as it progresses, treatment plans and therapies may need adjustments. This necessitates close and ongoing monitoring by healthcare providers. However, accessing healthcare regularly and adhering to treatment plans can be challenging for patients, particularly those who live in remote areas or have limited mobility.

Key Market Trends

Adoption of Minimally Invasive Procedures

The adoption of minimally invasive procedures is playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a progressive lung condition characterized by the destruction of lung tissue, has traditionally been associated with invasive surgical treatments or long-term medication. However, recent advancements in medical technology have led to the development and widespread adoption of minimally invasive procedures, offering a paradigm shift in the way emphysema is treated.

One of the most significant contributors to the growth of minimally invasive procedures is the emergence of bronchoscopic lung volume reduction (BLVR) techniques. BLVR involves the insertion of small devices or materials into the airways to block or reduce airflow to damaged lung areas. This procedure aims to improve lung function and alleviate symptoms without the need for open surgery. Patients benefit from shorter hospital stays, faster recovery times, and reduced risk of complications compared to traditional surgical approaches.

The appeal of minimally invasive procedures goes beyond their effectiveness; it lies in their patient-centric approach. Patients are more inclined to opt for less invasive treatments that offer quicker recovery times and a lower risk of complications. As a result, healthcare providers increasingly recommend and perform BLVR and other minimally invasive procedures, meeting the preferences and expectations of patients.

Moreover, the adoption of minimally invasive procedures aligns with the broader trend in healthcare toward value-based care and cost-effectiveness. These procedures typically lead to reduced healthcare costs due to shorter hospital stays and less post-operative care, benefiting both patients and healthcare systems.

Rise of Biologics in Emphysema Treatment

The rise of biologics in emphysema treatment is significantly boosting the Global Emphysema Treatment Market. Emphysema, a debilitating form of chronic obstructive pulmonary disease (COPD), has historically been treated with bronchodilators, corticosteroids, and oxygen therapy. However, recent advancements in medical science have led to the development and increasing use of biologics, representing a paradigm shift in the approach to managing this challenging respiratory condition.

Biologics are therapeutic agents derived from living organisms, such as monoclonal antibodies or proteins, designed to target specific molecular pathways involved in emphysema progression. Unlike traditional treatments that provide symptomatic relief, biologics offer a targeted approach, aiming to slow down the underlying disease process. This innovative approach has garnered significant attention and enthusiasm within the medical community and among patients.

One of the key advantages of biologics is their potential to improve lung function and overall quality of life for emphysema patients. By specifically targeting the molecular mechanisms responsible for the tissue destruction and inflammation seen in emphysema, these treatments have the potential to not only alleviate symptoms but also modify the course of the disease. This represents a fundamental shift from the traditional approach, which primarily focused on symptom management.

Additionally, biologics tend to have a favorable safety profile, reducing the risk of systemic side effects often associated with long-term use of corticosteroids or other medications. This makes biology an attractive option for patients and healthcare providers alike, especially for those who may have concerns about the potential risks and side effects of traditional treatments.

Segmental Insights

Treatment Insights

Based on the Treatment, Smoking Cessation emerged as the dominant segment in the global market for Global Emphysema Treatment Market in 2022. Smoking cessation is considered the most effective and primary preventive measure for emphysema. Since the leading cause of emphysema is long-term exposure to tobacco smoke, stopping smoking is crucial in preventing the disease from developing or progressing further. This has led to a significant emphasis on smoking cessation programs and interventions.

Smoking cessation is relatively cost-effective when compared to other emphysema treatments like gene therapy, surgery, or lung transplantation. This affordability makes it a practical choice for healthcare systems and individuals, especially when considering the long-term costs associated with managing emphysema.

Distribution Channel Insights

Based on the Distribution Channel, the Retail pharmacy segment emerged as the dominant player in the global market for Global Emphysema Treatment Market in 2022. Retail pharmacies are easily accessible to a vast majority of the population, whether in urban or rural areas. Patients with emphysema and other respiratory conditions often require regular access to medications and therapies. Retail pharmacies provide a convenient option for patients to obtain their prescriptions and medical supplies, promoting treatment adherence.

Retail pharmacy chains have a broad network of outlets, making it easy for patients to find a nearby pharmacy. This wide coverage ensures that emphysema medications and treatment supplies are readily available to patients across various geographical locations, both in cities and rural areas.

Regional Insights

North America emerged as the dominant player in the global Emphysema Treatment Market in 2022, holding the largest market share. North America, particularly the United States, has a significant prevalence of emphysema and other chronic obstructive pulmonary diseases (COPD). This high disease burden contributes to a substantial demand for emphysema treatment options, driving the market's growth. North America boasts advanced healthcare infrastructure, including well-equipped hospitals, specialized clinics, and a network of healthcare providers. This infrastructure supports the diagnosis, treatment, and management of emphysema with the latest medical technologies and therapies.

Key Market Players

• Icure Pharmaceuticals Inc.

• AstraZeneca Plc.

• Teva Pharmaceuticals Industries Ltd.

• Novartis AG

• GlaxoSmithKline Plc.

• Hikma Pharmaceuticals Plc

• Boehringer Ingelheim International GmbH

• Mylan N.V.

• Pfizer Inc.

• Orion Corporation

Report Scope:

In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Emphysema Treatment Market, By Treatment:

• Smoking Cessation
• Bronchodilators
• Steroids
• Leukotriene Modifiers
• Supplemental Oxygen
• Antibiotics
• Gene Therapy
• Surgery Transplant
• Other Treatments

Global Emphysema Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Global Emphysema Treatment Market, By End User:

• Hospitals &Clinics
• Ambulatory Surgical Centers
• Other

Global Emphysema Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Emphysema Treatment Market.

Available Customizations:

• Global Emphysema Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Emphysema Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments)
  • 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Distribution Channel
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Emphysema Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Distribution Channel
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Emphysema Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Distribution Channel
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Emphysema Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Distribution Channel
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Emphysema Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Distribution Channel
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Emphysema Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Distribution Channel
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Emphysema Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Distribution Channel
      • 5.3.5.2.3. By End-User

6. Europe Emphysema Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Distribution Channel
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Emphysema Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Distribution Channel
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Emphysema Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Distribution Channel
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Emphysema Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Distribution Channel
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Emphysema Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Distribution Channel
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Emphysema Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Distribution Channel
      • 6.3.5.2.3. By End-User

7. North America Emphysema Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Distribution Channel
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Emphysema Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Distribution Channel
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Emphysema Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Distribution Channel
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Emphysema Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Distribution Channel
      • 7.3.3.2.3. By End-User

8. South America Emphysema Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Distribution Channel
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Emphysema Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Distribution Channel
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Emphysema Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Distribution Channel
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Emphysema Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Distribution Channel
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Emphysema Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Distribution Channel
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Emphysema Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Distribution Channel
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Emphysema Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Distribution Channel
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Emphysema Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Distribution Channel
      • 9.3.3.2.3. By End-User
  • 9.3.4. Egypt Emphysema Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment
      • 9.3.4.2.2. By Distribution Channel
      • 9.3.4.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Emphysema Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Icure Pharmaceuticals Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. AstraZeneca Plc.
• 14.3. Teva Pharmaceuticals Industries Ltd.
• 14.4. Novartis AG
• 14.5. GlaxoSmithKline Plc.
• 14.6. Hikma Pharmaceuticals Plc
• 14.7. Boehringer Ingelheim International GmbH
• 14.8. Mylan N.V.
• 14.9. Pfizer Inc.
• 14.10. Orion Corporation

15. Strategic Recommendations

16. About Us & Disclaimer